Alan Kirschenbaum speaking at ACI Prescription Drug Pricing conference

Analyzing CMs/FDA Interplay in Government Payor Pricing and Reimbursement: Interpreting the Intent Behind the Inclusion of FDA Regulatory terminology in the AMP Draft Rule and understanding Its Repercussions

When

February 26, 2013

Alan Kirschenbaum is speaking on “Analyzing CMs/FDA Interplay in Government Payor Pricing and Reimbursement: Interpreting the Intent Behind the Inclusion of FDA Regulatory terminology in the AMP Draft Rule and understanding Its Repercussions” at the ACI Prescription Drug Pricing conference.

Doubletree Suites Times Square

New York, NY